AZN - AstraZeneca PLC

NYSE - Nasdaq Real Time Price. Currency in USD
36.04
-0.37 (-1.02%)
As of 3:41PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.41
Open36.08
Bid36.01 x 1200
Ask36.02 x 2200
Day's Range35.98 - 36.16
52 Week Range28.43 - 37.30
Volume1,531,297
Avg. Volume3,956,017
Market Cap90.87B
Beta0.58
PE Ratio (TTM)32.56
EPS (TTM)1.11
Earnings DateN/A
Forward Dividend & Yield1.40 (3.85%)
Ex-Dividend Date2018-02-15
1y Target Est39.09
Trade prices are not sourced from all markets
  • AstraZeneca CEO on immunotherapy, drug prices
    CNBC Videos14 days ago

    AstraZeneca CEO on immunotherapy, drug prices

    Pascal Soriot, AstraZeneca CEO, speaks to CNBC's Meg Tirrell at American Society of Clinical Oncology (ASCO) conference about the company's immunotherapy treatments, research and development and his thoughts on drug pricing.

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks3 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • 3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
    InvestorPlace4 days ago

    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

    In spite of a strong start in 2018, the pharma/biotech industry is struggling currently, presumably due to a shift in focus to lowering of high drug prices and faster approval of generics. This has led to an increase in merger & acquisition activity and may boost innovation and capital building in the biotech industry. Earlier in the year, we have seen Sanofi SA (NYSE:SNY) and Celgene Corporation (NASDAQ:CELG) acquiring smaller biotech companies.

  • The Wall Street Journal6 days ago

    [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials

    AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.

  • TheStreet.com6 days ago

    Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test

    have discontinued late-stage trials of their experimental Alzheimer's disease drug lanabecestat, sending both companies' stock prices down Tuesday. AstraZeneca's stock fell 22 cents to close at $36.16 a share, while Lilly dropped 35 cents to $85.49. "The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time, and we are deeply disappointed for the millions suffering from the devastating disease," Dr. Daniel Skovronsky, president of Lilly Research Labs, said in the statement.

  • AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap
    Investor's Business Daily6 days ago

    AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap

    AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.

  • Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
    Zacks6 days ago

    Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

    Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks6 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • Reuters6 days ago

    Lilly-AstraZeneca latest to abandon Alzheimer's drug trials

    Eli Lilly and Co and AstraZeneca Plc said on Tuesday they would discontinue late-stage trials testing their Alzheimer's treatment, the latest among a slew of drugmakers to stop developing treatments for the memory-robbing disease. The treatment, lanabecestat, belongs to a class of drugs called beta secretase cleaving enzyme (BACE) inhibitor, that blocks an enzyme involved in the production of a protein that creates brain plaques, considered a major cause of the disease. Experimental Alzheimer's drugs have had a dismal track record, with more than 100 failures, with Johnson and Johnson last month stopping mid-stage trials testing its BACE inhibitor drug.

  • Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests
    Bloomberg7 days ago

    Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests

    Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.

  • Financial Times7 days ago

    [$$] AstraZeneca and Eli Lilly scrap Alzheimer’s drug trial

    AstraZeneca and Eli Lilly are to halt a global trial of a drug meant to treat people suffering from early and mild forms of Alzheimer’s disease after a panel found the treatment was unlikely to meet its ...

  • AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
    Zacks7 days ago

    AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

    AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

  • What’s in AstraZeneca’s Research Pipeline for Fiscal 2019
    Market Realist7 days ago

    What’s in AstraZeneca’s Research Pipeline for Fiscal 2019

    In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline. A data readout is expected from the DECLARE trial for Farxiga for type 2 diabetes, and a regulatory decision in the European Union is expected for the Bydureon autoinjector for type 2 diabetes.

  • A Look At AstraZeneca’s Research Pipeline
    Market Realist7 days ago

    A Look At AstraZeneca’s Research Pipeline

    Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter. The company expects a data readout for Lynparza in an ovarian cancer indication. A regulatory decision is expected for Tagrisso in the European Union for lung cancer.

  • Analyzing AstraZeneca’s Cash Flow and Valuation
    Market Realist7 days ago

    Analyzing AstraZeneca’s Cash Flow and Valuation

    In the first quarter, AstraZeneca’s (AZN) cash outflow from operating activities rose YoY (year-over-year) to $140 million from $88 million, due to an increase in the movement of working capital and higher short-term provisions for the launch of new medicines. AstraZeneca generated $273 million from investing activities in the first quarter, compared with $146 million in Q1 2017. This change was due to lower capital expenditure and the timing of receipts on disposal of intangible assets.

  • What to Expect for AstraZeneca in Fiscal 2018
    Market Realist10 days ago

    What to Expect for AstraZeneca in Fiscal 2018

    AstraZeneca (AZN) has maintained its guidance for fiscal 2018. This expected growth in product sales is weighted towards the second half of the year, reflecting the impact of generic competition for Crestor in Europe and Japan and an increased revenue contribution from new medicines. AstraZeneca expects the sum of externalization revenue and other operating income and expenses to fall YoY (year-over-year).

  • How AstraZeneca Performed in the First Quarter
    Market Realist10 days ago

    How AstraZeneca Performed in the First Quarter

    In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.

  • Analysts’ Recommendations for AstraZeneca and Peers
    Market Realist10 days ago

    Analysts’ Recommendations for AstraZeneca and Peers

    Investors have a lot to watch for when it comes to AstraZeneca (AZN) stock, with key events expected in the company’s research pipeline and higher uptake expected for the company’s new medicines on the market. In this series, we’ll explore what analysts think of AstraZeneca’s stock potential, financial performance, valuation, and more. Of the six analysts covering AstraZeneca, four have recommended “buy” or a higher rating, while two have recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $39.09.

  • GlobeNewswire10 days ago

    New Research: Key Drivers of Growth for Ingersoll-Rand PLC, McEwen Mining, Sociedad Quimica y Minera S.A., AstraZeneca, Worldpay, and Silver Wheaton — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, June 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingersoll-Rand ...

  • PR Newswire12 days ago

    Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets

    NYSE:AZN) will lay the commercial groundwork in new emerging markets for the Chinese pharma's internal CNS pipeline. On May 7, Luye licensed exclusive rights to market the dibenzothiazepine atypical antipsychotic and its extended-release formulation, Seroquel XL, in 51 countries spanning developed and emerging markets. While Luye already markets products in developed and some emerging markets such as Russia and Indonesia, the deal will give Luye access to additional emerging markets including Mexico, Brazil, Saudi Arabia and South Africa.

  • PR Newswire12 days ago

    Seroquel Stepping Stone: How Luye Will Use Seroquel to Expand in Emerging Markets

    SHANGHAI , June 6, 2018 /PRNewswire/ -- The $538 million acquisition by Luye Pharma Group Ltd. (HKSE:2186) of Seroquel quetiapine fumarate from AstraZeneca plc (LSE:AZN; NYSE:AZN) will lay the commercial ...

  • Business Wire14 days ago

    LYNPARZA® (olaparib) in Combination With Abiraterone Delayed Disease Progression in Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data, which showed clinical improvement in median radiologic progression-free survival with LYNPARZA®  in combination with abiraterone compared to abiraterone monotherapy, a current standard of care, in metastatic castration-resistant prostate cancer .

  • Biogen Inc Stock Got an Upgrade, but Should You Listen?
    InvestorPlace14 days ago

    Biogen Inc Stock Got an Upgrade, but Should You Listen?

    Generally speaking, pharmaceuticals are experiencing a mixed year. After a promising start where Biogen shares closed out January up more than 8%, the momentum quickly collapsed. It wasn’t until the prior month that BIIB stock began to recover from its mess.

  • Analysts Give Mixed Recommendations for Novartis
    Market Realist14 days ago

    Analysts Give Mixed Recommendations for Novartis

    As discussed earlier, Novartis (NVS) reported EPS of $1.28 and revenue of $12.7 billion in the first quarter. In the second quarter, its revenue is expected to rise 7.8% year-over-year to $13.2 billion from $12.2 billion. The chart below shows analysts’ recommendations for Novartis over the last 12 months.

  • 3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
    Zacks14 days ago

    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

    Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.